Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-004966
Filing Date
2025-11-14
Accepted
2025-11-14 14:00:43
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9013
  Complete submission text file 0000902664-25-004966.txt   11200
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Subject) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91966 | Film No.: 251484287
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646
Business Address D81 CALLE C SUITE 301 PMB 1202 DORADO Puerto Rico 00646 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
LEI: 5493003YH8Q5SHT17216
Type: SCHEDULE 13G/A